Note 14 - Segment Information: Segment Information Table 1 (Tables)

9 Months Ended

Jan. 31, 2014

Tables/Schedules

Segment Information Table 1

	Three Months Ended January 31,		Nine Months Ended January 31,
	2014	2013	2014	2013
Revenues:
Chinese medicine – third party	$           713,896	$       1,111,530	$       1,862,718	$   2,475,830
Chinese medicine – related party	0	0	0	0
Total Chinese medicine	713,896	1,111,530	1,862,718	2,475,830
Stevioside – third party	1,680,795	687,414	4,338,845	3,615,509
Stevioside – related party	833,657	171,547	2,567,648	1,576,463
Total Stevioside	2,514,452	858,961	6,906,493	5,191,972
Total segment and consolidated revenues	$       3,228,348	$       1,970,491	$       8,769,211	$   7,667,802
Interest income (expense):
Chinese medicine	$                     92	$               1,667	$                   370	$           1,733
Stevioside	(35,573)	(1,030)	(69,101)	4,719
Corporate and other	0	0	0	1,718
Total segment and consolidated interest income (expense)	$           (35,481)	$                  637	$           (68,731)	$           8,170
Depreciation and amortization:
Chinese medicine	$             31,963	$             19,811	$             77,996	$         59,197
Stevioside	432,169	532,909	1,311,822	1,358,451
Corporate and other	81,294	0	243,881	0
Total segment and consolidated depreciation and amortization	$          545,426	$          552,720	$       1,633,699	$   1,417,648